Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00098774 · ClinicalTrials.gov registry record · Phase 2
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
A Phase 2 study of Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 20
- Study locations
NCT00098774: Completed Phase 2 study of Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.
NCT00098774 is a Phase 2 study of Lymphoma that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 47 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00098774, a Phase 2 study of Lymphoma, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving rituximab with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well rituximab given with combination chemotherapy works in treating patients with newly diagnosed primary CNS lymphoma.
Primary Outcome
Response is assessed by investigator according to Revised Response Criteria for Malignant Lymphoma. Complete response requires disappearance of all evidence of disease.
Conditions Studied
Interventions
- BIOLOGICAL rituximab
- DRUG etoposide
- DRUG leucovorin calcium
- BIOLOGICAL filgrastim
- DRUG cytarabine
Study Locations (20)
Missouri
- Truman Medical Center - Hospital Hill - Kansas City
- Saint Luke's Cancer Institute at Saint Luke's Hospital - Kansas City
- St. Joseph Medical Center - Kansas City
- North Kansas City Hospital - Kansas City
- Parvin Radiation Oncology - Kansas City
- CCOP - Kansas City - Kansas City
- Research Medical Center - Kansas City
- Saint Luke's East - Lee's Summit - Lee's Summit
- Liberty Hospital - Liberty
Kansas
- Menorah Medical Center - Overland Park
- Saint Luke's Hospital - South - Overland Park
- Shawnee Mission Medical Center - Shawnee Mission
Delaware
- Tunnell Cancer Center at Beebe Medical Center - Lewes
- CCOP - Christiana Care Health Services - Newark
California
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Illinois
- University of Chicago Cancer Research Center - Chicago
Indiana
- Fort Wayne Medical Oncology and Hematology - Fort Wayne
Iowa
- Hematology Oncology Associates of the Quad Cities - Bettendorf
Maryland
- Union Hospital Cancer Program at Union Hospital - Elkton MD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2004-10 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
What the finished NCT00098774 record still lists
NCT00098774 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which rituximab is the first listed.
NCT00098774 names 20 study sites across 9 states, led by Missouri, Kansas, Delaware.
Frequently Asked Questions
What is clinical trial NCT00098774 about?
NCT00098774 is a clinical study titled "Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma". RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spre...
What is the current status of trial NCT00098774?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2004-10. Estimated completion is 2014-09.
What conditions does trial NCT00098774 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00098774?
The interventions under investigation include: rituximab (BIOLOGICAL), etoposide (DRUG), leucovorin calcium (DRUG), filgrastim (BIOLOGICAL), cytarabine (DRUG).
Who is sponsoring clinical trial NCT00098774?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00098774 being conducted?
This trial has 20 study locations across California, Delaware, Illinois, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00098774's enrollment target sits among peer trials
47 160th of 299 higher than 139 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia